Incretin Atlas › Trials › TRIUMPH-OUTCOMES
TRIUMPH-OUTCOMES
Retatrutide · Obesity + CVD
Design
- Molecule(s)
- Retatrutide
- Population
- Obesity + CVD
- Official title
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- active not recruiting · 2024-04 → 2029-02
- Participants
- 10000
- Registry
- NCT06383390
Ongoing outcome trial
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| TRIUMPH-OUTCOMES | Retatrutide | Obesity + CVD Obesity (BMI ≥27) + ASCVD, with or without T2D | MACE | 10000 | active not recruiting | 2029-02 | NCT06383390 |
No results yet; the primary completion date comes from the registry.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRIUMPH-OUTCOMES. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-outcomes/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.